Complex oversight governs the Sertraline Hydrochloride Tablet Market across jurisdictions. The FDA regulates sertraline as a prescription drug requiring approved New Drug Applications or Abbreviated New Drug Applications for generics. The Sertraline Hydrochloride Tablet Market must comply with stringent bioequivalence requirements for generic approval through pharmacokinetic studies. European Medicines Agency oversight includes centralized and decentralized authorization procedures. Risk Evaluation and Mitigation Strategies address suicidality warnings, particularly for pediatric and young adult populations. Controlled substance scheduling varies globally, though sertraline remains uncontrolled in most jurisdictions. Labeling requirements include black box warnings, medication guides, and patient counseling information. Post-marketing surveillance through adverse event reporting maintains safety databases. International Council for Harmonisation guidelines streamline multi-regional development and registration processes.